Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

9.0%

134 terminated/withdrawn out of 1483 trials

Success Rate

87.6%

+1.1% vs industry average

Late-Stage Pipeline

8%

120 trials in Phase 3/4

Results Transparency

30%

284 of 944 completed trials have results

Key Signals

245 recruiting284 with results101 terminated33 withdrawn

Enrollment Performance

Analytics

N/A
310(37.5%)
Phase 2
229(27.7%)
Phase 1
149(18.0%)
Phase 3
93(11.3%)
Phase 4
27(3.3%)
Early Phase 1
18(2.2%)
826Total
N/A(310)
Phase 2(229)
Phase 1(149)
Phase 3(93)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (1483)

Showing 20 of 1483 trials
NCT05375812Recruiting

NIH Investigative Deep Phenotyping Study of Gulf War Veteran Health (Project NIH IN-DEPTH)

Role: lead

NCT04106466Not ApplicableActive Not Recruiting

DBS for TRD With the Medtronic Summit RC+S

Role: collaborator

NCT02107989Recruiting

Noninvasive Pre-surgical Evaluation of Patients With Focal Epilepsy and Establishment of a Normative Imaging Database

Role: lead

NCT06707207Recruiting

Predicting Future Errors During Skill Performance

Role: lead

NCT06615973Recruiting

Screening for Social Determinants of Health (SDOH) and Cognitive Function in Individuals With History of Stroke

Role: lead

NCT05611918Active Not Recruiting

REpeated ASSEssment of SurvivorS in Intracerebral Hemorrhage Study

Role: collaborator

NCT06052605Not ApplicableRecruiting

Healthy Aging in People With Epilepsy Program

Role: collaborator

NCT01287156Completed

Evaluation and Diagnosis of Potential Research Subjects With Traumatic Brain Injury

Role: collaborator

NCT02522611Phase 1Not Yet Recruiting

Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain

Role: lead

NCT07416188Phase 1Recruiting

Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

Role: lead

NCT07388550Phase 1Not Yet Recruiting

Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)

Role: lead

NCT01019343Not ApplicableCompleted

Physiological Investigations of Movement Disorders

Role: lead

NCT05350774Phase 2Enrolling By Invitation

Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2

Role: lead

NCT07137442Recruiting

Distinguishing Tics and Functional Tics Using Clinical Neurophysiological Techniques

Role: lead

NCT02531880Phase 1Recruiting

Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy

Role: lead

NCT00073801Completed

Pelvic Pain in Women With Endometriosis

Role: lead

NCT07511049Phase 2Recruiting

Intravenous Brincidofovir as an Antiviral for Treatment of Progressive Multifocal Leukoencephalopathy: A Pilot Study

Role: lead

NCT05047172Phase 3Active Not Recruiting

Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis

Role: collaborator

NCT07256795Enrolling By Invitation

Blood-Brain Barrier Integrity and Immune Dynamics in Neuropsychiatric Sequelae of Post-SARS-CoV-2 Onset ME/CFS Versus Pre-Pandemic ME/CFS Patients

Role: collaborator

NCT06002945Completed

Exploring Outcomes and Characteristics of Myasthenia Gravis 2

Role: collaborator